Compositions comprising an aryl pyrazole and/or a formamidine, methods and uses thereof
This invention relates to compositions for combating parasites in animals, comprising 1-arylpyrazole compounds alone or in combination with formamidine compounds. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infestation in an animal comprising administering the compositions of the invention to the animal in need thereof.
1. A composition for the treatment of a parasitic infestation in an animal comprising at least one 1-arylpyrazole compound of formula (IB):
wherein:
R 1b is alkyl, CN or halogen;
R 2b is S(O) n R 14b or 4,5-dicyanoimidazol-2-yl or haloalkyl;
R 14b is alkyl or haloalkyl;
R 3b is a hydrogen, halogen, —NR 7b R 8b , —S(O) m R 9b , —C(O)R 9b , —C(O)OR 9b , alkyl, haloalkyl, —OR 10b or an —N═C(R 11b )(R 12b );
R 6b is a halogen, haloalkyl, haloalkoxy, S(O) q CF 3 or SF 5 group;
R 7B and R 8B independently represent a hydrogen, alkyl, haloalkyl, —C(O)alkyl, —S(O) r CF 3 , acyl or alkoxycarbonyl; or
R 7b and R 8b can together form a divalent alkylene radical which is optionally interrupted by one or two divalent heteroatoms;
R 9b is an alkyl or haloalkyl;
R 10b is hydrogen, alkyl or haloalkyl;
R 11b is hydrogen or alkyl radical;
R 12b is an optionally substituted aryl or an optionally substituted heteroaryl group;
R 4b and R 13b represent, independently of one another, hydrogen, halogen CN or NO 2 ;
m, n, q and r represent, independently of one another, an integer equal to 0, 1 or 2; and
Z represents a trivalent nitrogen atom or a C-R 13b radical, the three other valencies of the carbon atom forming part of the aromatic ring,
in a first veterinarily acceptable carrier;
at least one formamidine compound of formula (II):
wherein:
x is an integer from 0-5;
R 14 is alkyl, halogen or —OC(═O)NR a R b ,
wherein R a and R b are independently hydrogen or alkyl;
R 15 is hydrogen or alkyl;
R 16 is hydrogen or alkyl; and
R 17 is hydrogen, alkyl or
in a second veterinarily acceptable carrier; and optionally at least one crystallization inhibitor, wherein the 1-arylpyrazole compound(s) and first veterinarily acceptable carrier are compartmentalized together, and not in fluid communication with, the formamidine compound(s) and the second veterinarily acceptable carrier.
2. The composition of claim 1 , wherein the 1-arylpyrazole compound(s) of Formula (IB) and the first veterinarily acceptable carrier are in one cavity of a dual-cavity container and the formamidine compound(s) of Formula (II) and the second veterinarily acceptable carrier are in a second cavity of a dual-cavity container, wherein the first cavity is defined by a front wall and a divider wall; and the second cavity is defined by a rear wall and the divider wall.
3. The composition of claim 1 , wherein in the 1-arylpyrazole of Formula (IB):
R 1b is methyl, CN or halogen;
R 2b is S(O) n R 14b ;
R 14b is C 1 -C 6 -alkyl or C 1 -C 6 -haloalkyl;
R 3b is —NR 7b R 8b ,
R 7b and R 8b independently represent a hydrogen, C 1 -C 6 -alkyl, C 1 -C 6 -haloalkyl, —C(O)C 1 -C 6 -alkyl, —S(O) r CF 3 , C 1 -C 6 -acyl or C 1 -C 6 -alkoxycarbonyl radical;
R 6b is a halogen, C 1 -C 6 -haloalkyl, or C 1 -C 6 -haloalkoxy;
m, n, q and r represent, independently of one another, an integer equal to 0 or 1; and
Z is a C-R 13b radical.
4. The composition of claim 1 , wherein in the 1-arylpyrazole of Formula (IB):
R 1b is methyl, CN or halogen;
R 2b is S(O) n R 14b ;
R 14b is C 1 -C 6 -alkyl or C 1 -C 6 -haloalkyl;
R 3b is alkyl or haloalkyl;
R 6b is a halogen, C 1 -C 6 -haloalkyl, or C 1 -C 6 -haloalkoxy;
m, n, q and r represent, independently of one another, an integer equal to 0 or 1; and
Z is a C—R 13b radical.
5. The composition of claim 1 , wherein the first veterinarily acceptable carrier comprises acetone, acetonitrile, benzyl alcohol, ethanol, isopropanol, diisobutyl adipate, diisopropyl adipate, butyl diglycol, dipropylene glycol n-butyl ether, ethylene glycol monoethyl ether, ethylene glycol monomethyl ether, dipropylene glycol monomethyl ether, liquid polyoxyethylene glycols, propylene glycol monomethyl ether, propylene glycol monoethyl ether, 2-pyrrolidone, N-methylpyrrolidone, diethylene glycol monoethyl ether, triacetin, butyl acetate, octyl acetate, propylene carbonate, butylene carbonate, dimethyl sulfoxide, an amide, dimethylformamide, dimethylacetamide, or any combination thereof.
6. The composition of claim 1 , wherein the second veterinarily acceptable carrier comprises aryl ethers, alkoxybenzene compounds, aliphatic carboxylic acid esters, aromatic carboxylic acid esters, aliphatic ketones, cyclic ketones, or mixtures thereof.
7. The composition of claim 1 , wherein the second veterinarily acceptable carrier comprises methoxybenzene, butyl acetate, benzyl acetate, methyl isobutyl ketone, ethyl benzoate, benzyl benzoate, octyl acetate, or mixtures thereof.
8. The composition of claim 1 , wherein the second veterinarily acceptable carrier comprises an aprotic solvent with a dielectric constant of about 2 to about 30.
9. The composition of claim 1 , wherein at least one formamidine compound is amitraz, formetanate, chloromebuform, formparanate or chlodimeform.
10. A method for the treatment of a parasitic infestation in an animal comprising administering an effective amount of the composition of claim 1 to the animal.
11. The method of claim 10 , wherein at least one 1-arylpyrazole compound is fipronil.
12. The method of claim 10 , wherein at least one formamidine compound is amitraz.
13. The method of claim 10 , wherein the composition is administered using a dual-cavity container, wherein the 1-arylpyrazole compound(s) and the first veterinarily acceptable carrier are administered from a first cavity of the dual-cavity container and the formamidine compound(s) and the second veterinarily acceptable carrier are administered from a second cavity of the dual-cavity container.
14. The method of claim 12 , wherein the 1-arylpyrazole compound(s) and the formamidine compound(s) are administered simultaneously.
15. The composition of claim 1 , wherein the first veterinarily acceptable carrier comprises an organic solvent with a dielectric constant of about 10 to about 35.
16. The composition of claim 15 , wherein the first veterinarily acceptable carrier comprises C 1 -C 10 alcohols or esters thereof, C 10 -C 18 saturated fatty acids or esters thereof, C 10 -C 18 monounsaturated fatty acids or esters thereof, monoesters or diesters of aliphatic diacids, glycerol monoesters, glycerol diesters, glycerol triesters, glycols, glycol ethers, glycol esters, glycol carbonates, polyethylene glycols or monoethers, diethers, monoesters or diesters thereof.
17. The composition of claim 16 , wherein the first veterinarily acceptable carrier comprises a C 1 -C 10 alcohol, a glycol ether, a polyethylene glycol monoether or a polyethylene glycol diether, or a mixture thereof.
18. The composition of claim 1 , wherein the 1-arylpyrazole of Formula (IB) is fipronil.
19. The composition of claim 1 , wherein the 1-arylpyrazole of Formula (IB) is amitraz.
20. The composition of claim 18 , wherein fipronil is present at a concentration of about 5% (w/v) to about 15% (w/v).
21. The composition of claim 19 , wherein amitraz is present at a concentration of about 1% (w/v) to about 30% (w/v).
22. The composition of claim 1 , wherein the composition comprises fipronil at a concentration of about 5% (w/v) to about 15% (w/v) and amitraz at a concentration of about 5% (w/v) to about 20% (w/v).
23. The composition of claim 1 , wherein the composition further comprises an additional parasiticidal active agent.
24. The composition of claim 23 , wherein the additional parasiticidal active agent is an avermectin or milbemycin compound, an insect growth regulator, a pyrethroid, a benzimidazole, an imidazothiazole, praziquantel, an isoxazoline compound, an amino acetonitrile compound or an aryloazol-2-yl cyanoethylamino compound.
25. The composition of claim 24 , wherein the insect growth regulator is methoprene or pyriproxyfen.
26. The composition of claim 24 , wherein the avermectin or milbemycin compound is abamectin, dimadectin, doramectin, emamectin, eprinomectin, ivermectin, latidectin, lepimectin, selamectin, milbemectin, milbemycin D, moxidectin, nemadectin or milbemycin oxime.
27. The composition of claim 1 , wherein the composition comprises fipronil at a concentration of about 5% (w/v) to about 15% (w/v) and amitraz at a concentration of about 5% to about 20% (w/v); wherein the first veterinarily acceptable carrier comprises ethanol, isopropanol, diethyleneglycol monoethyl ether, N-methylpyrrolidone, or a mixture thereof; and wherein the second veterinarily acceptable carrier comprises methoxybenzene, butyl acetate, benzyl acetate, ethyl benzoate, benzyl benzoate or octyl acetate, or a mixture thereof.